Clinical Trials

Gilead’s liver disease drug selonsertib fails to meet primary endpoint in Stellar-4 study

Gilead Sciences has announced topline data from the phase 3 Stellar-4 study of its liver disease treatment selonsertib in compensated cirrhosis (F4) due to nonalcoholic steatohepatitis (NASH).

NeoTX enters into immuno-oncology clinical trial collaboration with AstraZeneca

NeoTX Therapeutics has entered into a clinical collaboration with AstraZeneca Group’s global biologics research and development arm, MedImmune to support Phase 1b/2 studies investigating NeoTX’s naptumomab estafenatox in combination with IMFINZI (durvalumab).

Moderna announces dosing of first monoclonal antibody encoded by mRNA in clinical trial

Moderna has announced the dosing of the first subject in a phase 1 clinical trial evaluating the safety and tolerability of escalating doses of mRNA-1944 via intravenous infusion in healthy adults.

Eisai, Purdue Pharma present efficacy and safety data from second phase 3 study of lemborexant

Eisai and Purdue Pharma announced six-month results from SUNRISE 2, a long-term Phase 3 clinical study evaluating the efficacy and safety of lemborexant, an investigational agent being developed for the treatment of insomnia, a sleep-wake disorder.

Verseon begins dosing in phase 1 trial of VE-1902 oral anticoagulant

Verseon has started dosing of its lead blood thinner candidate VE-1902 in a phase 1 trial held in healthy volunteers at Nucleus Network in Melbourne, Australia.

Newron completes patient enrollment in STARS Study

Newron Pharmaceuticals has announced the successful completion of patient enrollment in its STARS (Sarizotan for the Treatment of Apneas in Rett Syndrome) clinical study.

Eureka Therapeutics announces US FDA clearance of IND application for trial of ET140202 Artemis T-Cell therapy

Eureka Therapeutics, a clinical stage biotechnology company developing antibody-TCR (AbTCR) T-cell therapies, announced that the US Food and Drug Administration (FDA) has cleared its investigational new drug (IND) application for ET140202 ARTEMIS T-cell therapy in AFP-positive patients with advanced hepatocellular carcinoma (HCC), the most common type of liver cancer.

Genentech halts two phase 3 AD trials of crenezumab over futility

Roche’s Genentech has decided to stop two phase 3 trials evaluating its anti-beta-amyloid molecule crenezumab in early Alzheimer’s disease (AD) for futility reasons.

Pfizer and Lilly’s tanezumab succeeds in second phase 3 osteoarthritis pain trial

Pfizer and Eli Lilly have announced positive top-line results from a phase 3 study evaluating tanezumab 2.5 mg or 5 mg in patients with moderate-to-severe osteoarthritis (OA) pain.